Shang Hai Zheng Quan Bao·2025-10-08 19:00Core Viewpoint - The lawsuit involving BeiGene and Pharmacyclics has been voluntarily withdrawn, resulting in no negative impact on the company's operations or product development in the U.S. market [2][5][4]. Group 1: Lawsuit Details - On June 13, 2023, Pharmacyclics LLC filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming patent infringement related to the product 百悦泽? [3]. - The patent in question is U.S. Patent No. 11,672,803, which was granted to Pharmacyclics on the same day the lawsuit was filed [3]. - The court has agreed to pause the infringement lawsuit pending the outcome of a Patent Trial and Appeal Board (PTAB) review, which is expected to conclude by November 1, 2023 [3]. Group 2: Impact on the Company - The lawsuit has not adversely affected the research and sales of 百悦泽? in the U.S. market, nor has it significantly impacted the company's overall operations [5]. - The company maintains confidence in its intellectual property related to 百悦泽? and plans to continue developing innovative cancer treatment solutions [2][5].